Deep Pockets Can't Save Blech's Biotech Empire

When D. Blech & Co. closed its doors on Sept. 23, the event ended a costly, two-year struggle by financier David Blech to shore up his vast biotechnology holdings. Blech had laid out massive amounts of his own money. But the stock prices in his startup ventures kept falling, and ultimately, his company couldn't meet capital requirements.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.